A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT03797261 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Safety

Conditions

Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma

Interventions

DRUG: Venetoclax
DRUG: AMG 176

Sponsor

AbbVie

Collaborators

[object Object]
[object Object]